Low Bone Mineral Density and High Bone Turnover in Patients With Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective Study.

Abstract

Chemotherapy associated osteoporosis is a severe problem in patients with malignant diseases as it increases the risk for fractures and deteriorates quality of life. There are very limited data in the literature for the effect of chemotherapy on bone metabolism of adult patients with Non-Hodgkin Lymphoma (NHL). We prospectively evaluated bone remodeling pre- and post-chemotherapy in 61 patients with newly diagnosed NHL. First-line chemotherapy resulted in high bone turnover, which led to increased bone loss and reduced bone mineral density (BMD) of lumbar spine (L1-L4) and femur neck (FN). The reduction of L1-L4 and FN BMD post-chemo was more profound in males and in older patients (>55 years). Patients who received 8 cycles of chemotherapy had a greater reduction of L1-L4 and FN BMD as compared to 6 cycles. The administration of chemotherapy also resulted in a dramatic increase of bone resorption markers (CTX and TRACP-5b), bone formation markers, (bALP and Osteocalcin) and of osteoblast regulator Dickkopf-1. During study period, one patient had a pathological fracture in his right FN.

• Authors: Konstantinos Anargyrou, Despina Fotiou, Theodoros P Vassilakopoulos, Dimitrios Christoulas, Polyzois Makras, Maria Dimou, Ioannis Ntanasis-Stathopoulos, Stavroula Masouridou, Maria K Angelopoulou, Athanasios Papatheodorou, Konstantinos Tsionos, Panayiotis Panayiotidis, Meletios A Dimopoulos, Evangelos Terpos
• Journal: HemaSphere (Hemasphere) Vol. 3 Issue 6 Pg. e303 (Dec 2019) ISSN: 2572-9241 [Electronic] United States
• PMID: 31976477 (Publication Type: Journal Article)
• Copyright: Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.